Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-31T17:13:23.142Z Has data issue: false hasContentIssue false
  • English
  • Français

d-Cycloserine Addition to Exposure Sessions in the Treatment of Patients With Obsessive-Compulsive Disorder

Published online by Cambridge University Press:  10 November 2016

A.S. de Leeuw ,
H.J.G.M. van Megen ,
R.S. Kahn  and
H.G.M. Westenberg
A.S. de Leeuw*
Affiliation:
Marina de Wolfcenter, Innova, GGz Centraal, Ermelo, The Netherlands
H.J.G.M. van Megen
Affiliation:
Marina de Wolfcenter, Innova, GGz Centraal, Ermelo, The Netherlands
R.S. Kahn
Affiliation:
Department of psychiatry, Rudolf Magnus institute of neuroscience, university medical center, Utrecht, The Netherlands
H.G.M. Westenberg
Affiliation:
Department of psychiatry, Rudolf Magnus institute of neuroscience, university medical center, Utrecht, The Netherlands
*
* Corresponding author. at: Altrecht Academic Anxiety Center, Nieuwe Houtenseweg 12, 3524 SH, Utrecht, The Netherlands. Tel.: +31 30 2308790 E-mail address:[email protected] (A.S. de Leeuw).
Get access

Abstract

Background

Preliminary studies have shown that the addition of the partial NMDA-agonist d-cycloserine (DCS) might be promising in enhancing the results of exposure therapy in obsessive-compulsive disorder (OCD). We examined the effect of DCS addition to exposure therapy in a somewhat larger sample of OCD patients with special attention to subgroups, because of the heterogeneity of OCD.

Methods

A randomized, double-blind, placebo controlled trial was conducted in 39 patients with OCD. Patients received 6 guided exposure sessions, once a week. One hour before each session 125 mg DCS or placebo was administered.

Results

Scores on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) declined more in the DCS group than in the placebo group, but the difference did not reach statistical significance (P = 0.076, partial η2 = 0.13). Response percentages also did not differ between the DCS and the placebo group (37% and 15% respectively). In the ‘cleaning/contamination’ subgroup a significant effect was found in favour of DCS (P = 0.033, partial η2 = 0.297).

Conclusions

The results of this study did not support the application of DCS to exposure therapy in OCD. Some specific aspects need further investigation: efficacy of DCS in a larger ‘cleaning/contamination’ (sub-)group, DCS addition only after successful sessions, interaction with antidepressants.

Keywords

d-cycloserineObsessive-compulsive disorderExposure and response prevention
Type
Original article
Information
European Psychiatry , Volume 40 , February 2017 , pp. 38 - 44
Copyright
Copyright © Elsevier Masson SAS 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

1

Deceased.

References

Blier, P.Habib, R.Flament, M.F.Pharmacotherapies in the management of obsessive-compulsive disorder. Can J Psychiatry 2006; 51(7): 417–430CrossRefGoogle ScholarPubMed
Dell’Osso, B.Nestadt, G.Allen, A.Hollander, E.Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: a critical review. J Clin Psychiatry 2006; 67(4): 600–61010.4088/JCP.v67n0411CrossRefGoogle ScholarPubMed
Abramowitz, J.S.The psychological treatment of obsessive-compulsive disorder. Can J Psychiatry 2006; 51(7): 407–416CrossRefGoogle ScholarPubMed
Neziroglu, F.Henricksen, J.Yaryura-Tobias, J.A.Psychotherapy of obsessive-compulsive disorder and spectrum: established facts and advances, 1995–2005. Psychiatr Clin North Am 2006; 29(2): 585–604CrossRefGoogle ScholarPubMed
Fisher, P.L.Wells, A.How effective are cognitive and behavioral treatments for obsessive-compulsive disorder? A clinical significance analysis. Behav Res Ther 2005; 43(12): 1543–1558CrossRefGoogle ScholarPubMed
Eddy, K.T.Dutra, L.Bradley, R.Westen, D.A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 2004; 24(8): 1011–1030CrossRefGoogle ScholarPubMed
Franklin, M.E.Foa, E.B.Treatment of obsessive compulsive disorder. Annu Rev Clin Psychol 2011; 7: 229–243CrossRefGoogle ScholarPubMed
Foa, E.B.Liebowitz, M.R.Kozak, M.J.Davies, S.Campeas, R.Franklin, M.E.et al.Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder Am J Psychiatry 2005; 162(1): 151–161CrossRefGoogle ScholarPubMed
Rothbaum, B.O.Critical parameters for d-cycloserine enhancement of cognitive-behaviorial therapy for obsessive-compulsive disorder. Am J Psychiatry 2008; 165(3): 293–296CrossRefGoogle ScholarPubMed
Norberg, M.M.Krystal, J.H.Tolin, D.F.A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008; 63(12): 1118–112610.1016/j.biopsych.2008.01.012CrossRefGoogle ScholarPubMed
Rachman, S.Hodgson, R.Englewood Cliffs NJ: Prentice Hall; 1980Google Scholar
Storch, E.A.Merlo, L.J.Bengtson, M.Murphy, T.K.Lewis, M.H.Yang, M.C.et al.d-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder Int Clin Psychopharmacol 2007; 22(4): 230–237CrossRefGoogle Scholar
Kushner, M.G.Kim, S.W.Donahue, C.Thuras, P.Adson, D.Kotlyar, M.et al.d-cycloserine augmented exposure therapy for obsessive-compulsive disorder Biol Psychiatry 2007; 62(8): 835–83810.1016/j.biopsych.2006.12.020CrossRefGoogle ScholarPubMed
Wilhelm, S.Buhlmann, U.Tolin, D.F.Meunier, S.A.Pearlson, G.D.Reese, H.E.et al.Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008; 165(3): 335–341 [quiz 409]CrossRefGoogle ScholarPubMed
Storch, E.A.Murphy, T.K.Goodman, W.K.Geffken, G.R.Lewin, A.B.Henin, A.et al.A preliminary study of d-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder Biol Psychiatry 2010; 68(11): 1073–1076CrossRefGoogle ScholarPubMed
Farrell, L.Waters, A.Boschen, M.Hattingh, L.McConnell, H.Milliner, E.et al.Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of d-cycloserine-augmented behavior therapy Depress Anxiety 2013; 30(8): 723–731CrossRefGoogle ScholarPubMed
Mataix-Cols, D.Turner, C.Monzani, B.Isomura, K.Murphy, C.Krebs, G.et al.Cognitive-behavioural therapy with post-session d-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial Br J Psychiatry 2014; 204(1): 77–78CrossRefGoogle ScholarPubMed
Chasson, G.S.Buhlmann, U.Tolin, D.F.Rao, S.R.Reese, H.E.Rowley, T.et al.Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine Behav Res Ther 2010; 48(7): 675–679CrossRefGoogle ScholarPubMed
Knopp, J.Knowles, S.Bee, P.Lovell, K.Bower, P.A systematic review of predictors and moderators of response to psychological therapies in OCD: do we have enough empirical evidence to target treatment?. Clin Psychol Rev 2013; 33(8): 1067–1081CrossRefGoogle ScholarPubMed
Thiel, N.Hertenstein, E.Nissen, C.Herbst, N.Külz, A.K.Voderholzer, U.The effect of personality disorders on treatment outcomes in patients with obsessive-compulsive disorders. J Personal Disord 2013; 27(6): 697–715CrossRefGoogle ScholarPubMed
Williams, M.T.Farris, S.G.Turkheimer, E.N.Franklin, M.E.Simpson, H.B.Liebowitz, M.et al.The impact of symptom dimensions on outcome for exposure and ritual prevention therapy in obsessive-compulsive disorder J Anxiety Disord 2014; 28(6): 553–558CrossRefGoogle ScholarPubMed
First, M.B.Spitzer, R.L.Gibbon, M.Williams, J.B.Structured Clinical Interview for DSM-IV axis disorders Washington, DC: American Psychiatric Press; 1998Google Scholar
Goodman, W.K.Price, L.H.Rasmussen, S.A.Mazure, C.Fleischmann, R.L.Hill, C.L.et al.The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability Arch Gen Psychiatry 1989; 46(11): 1006–1011CrossRefGoogle ScholarPubMed
Goodman, W.K.Price, L.H.Rasmussen, S.A.Mazure, C.Delgado, P.Heninger, G.R.et al.The Yale-Brown Obsessive Compulsive Scale. II. Validity Arch Gen Psychiatry 1989; 46(11): 1012–1016CrossRefGoogle ScholarPubMed
Arindell, W.A.de Vlaming, I.H.De Yale-Brown Obsessive Compulsive Scale-Nederlandse bewerking (Y-BOCS-NL): onderscheidend vermogen. Diagnostiek-Wijzer 2000; 3: 90–95Google Scholar
Sanavio, E.Obsessions and compulsions: the Padua Inventory. Behav Res Ther 1988; 26(2): 169–177CrossRefGoogle ScholarPubMed
Van Oppen, P.Hoekstra, R.J.Emmelkamp, P.M.The structure of obsessive-compulsive symptoms. Behav Res Ther 1995; 33(1): 15–23CrossRefGoogle ScholarPubMed
Guy, W.The Clinical Global Impressions Scale Rockville, Md: National Institute of Mental Health; 1976 217–222Google Scholar
Beck, A.T.Steer, R.A.Manual for the revised Beck Depression Inventory San Antonio, TX: Psychological Corperation; 1987Google Scholar
van der Does, A.J.W.Handleiding bij de Nederlandse bewerking van de BDI-II San Antonio, TX/Lisse: The Psychological Corporation/Swets Test Publishers; 2002Google Scholar
Raine, A.The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull 1991; 17(4): 555–564CrossRefGoogle ScholarPubMed
Vollema, M.G.Hoijtink, H.The multidimensionality of self-report schizotypy in a psychiatric population: an analysis using multidimensional Rasch models. Schizophr Bull 2000; 26(3): 565–575CrossRefGoogle Scholar
Mataix-Cols, D.Rosario-Campos, M.C.Leckman, J.F.A multidimensional model of obsessive-compulsive disorder. Am J Psychiatry 2005; 162(2): 228–238CrossRefGoogle ScholarPubMed
van Berckel, B.N.Lipsch, C.Gispen-de Wied, C.Wynne, H.J.Blankenstein, M.A.van Ree, J.M.et al.The partial NMDA agonist d-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacology (Berl) 1998; 138(2): 190–197CrossRefGoogle ScholarPubMed
van Berckel, B.N.Lipsch, C.Timp, S.Gispen-de Wied, C.Wynne, H.van Ree, J.M.et al.Behavioral and neuroendocrine effects of the partial NMDA agonist d-cycloserine in healthy subjects. Neuropsychopharmacology 1997; 16(5): 317–324CrossRefGoogle ScholarPubMed
Ressler, K.J.Rothbaum, B.O.Tannenbaum, L.Anderson, P.Graap, K.Zimand, E.et al.Cognitive enhancers as adjuncts to psychotherapy: use of d-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61(11): 1136–1144CrossRefGoogle Scholar
Quirk, G.J.Mueller, D.Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacology 2008; 33: 56–72CrossRefGoogle ScholarPubMed
Andersson, E.Hedman, E.Enander, J.Radu Djurfeldt, D.Ljotsson, B.Cervenka, S.et al.d-Cycloserine vs placebo as adjunct to cognitive behavioral therapy for obsessive-compulsive disorder and interaction with antidepressants: a randomized clinical trial. JAMA Psychiatry 2015; 72(7): 659–667CrossRefGoogle ScholarPubMed
Tolin, D.F.Abramowitz, J.S.Diefenbach, G.J.Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown Obsessive Compulsive Scale. J Clin Psychiatry 2005; 66(12): 1549–1557CrossRefGoogle ScholarPubMed
Lewin, A.B.De Nadai, A.S.Park, J.Goodman, W.K.Murphy, T.K.Storch, E.A.Refining clinical judgment of treatment outcome in obsessive-compulsive disorder. Psychiatry Res 2011; 185(3): 394–401CrossRefGoogle ScholarPubMed
Farris, S.G.McLean, C.P.Van Meter, P.E.Simpson, H.B.Foa, E.B.Treatment response, symptom remission, and wellness in obsessive-compulsive disorder. J Clin Psychiatry 2013; 74(7): 685–690CrossRefGoogle ScholarPubMed
Parnas, A.S.Weber, M.Richardson, R.Effects of multiple exposures to d-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem 2005; 83(3): 224–231CrossRefGoogle ScholarPubMed
Bontempo, A.Panza, K.E.Bloch, M.H.d-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis. J Clin Psychiatry 2012; 73(4): 533–537CrossRefGoogle ScholarPubMed
van den Heuvel, O.A.Remijnse, P.L.Mataix-Cols, D.Vrenken, H.Groenewegen, H.J.Uylings, H.B.et al.The major symptom dimensions of obsessive-compulsive disorder are mediated by partially distinct neural systems. Brain 2009; 132(Pt 4):853–868CrossRefGoogle ScholarPubMed
Iervolino, A.C.Rijsdijk, F.V.Cherkas, L.Fullana, M.A.Mataix-Cols, D.A multivariate twin study of obsessive-compulsive symptom dimensions. Arch Gen Psychiatry 2011; 68(6): 637–644CrossRefGoogle ScholarPubMed
Harrison, B.J.Pujol, J.Cardoner, N.Deus, J.Alonso, P.Lopez-Sola, M.et al.Brain corticostriatal systems and the major clinical symptom dimensions of obsessive-compulsive disorder. Biol Psychiatry 2013; 73(4): 321–328CrossRefGoogle ScholarPubMed
Abramowitz, J.S.Franklin, M.E.Schwartz, S.A.Furr, J.M.Symptom presentation and outcome of cognitive-behavioral therapy for obsessive-compulsive disorder. J Consult Clin Psychol 2003; 71(6): 1049–1057CrossRefGoogle ScholarPubMed
Rufer, M.Fricke, S.Moritz, S.Kloss, M.Hand, I.Symptom dimensions in obsessive-compulsive disorder: prediction of cognitive-behavior therapy outcome. Acta Psychiatr Scand 2006; 113(5): 440–446CrossRefGoogle ScholarPubMed
Stein, D.J.Carey, P.D.Lochner, C.Seedat, S.Fineberg, N.Andersen, E.W.Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy. CNS Spectr 2008; 13(6): 492–498CrossRefGoogle ScholarPubMed
Shetti, C.N.Reddy, Y.C.Kandavel, T.Kashyap, K.Singisetti, S.Hiremath, A.S.et al.Clinical predictors of drug nonresponse in obsessive-compulsive disorder. J Clin Psychiatry 2005; 66(12): 1517–1523CrossRefGoogle ScholarPubMed
Visser, H.A.van Oppen, P.van Megen, H.J.Eikelenboom, M.van Balkom, A.J.Obsessive-compulsive disorder; chronic versus non-chronic symptoms. J Affect Disord 152–154 2014 169–17410.1016/j.jad.2013.09.004CrossRefGoogle Scholar
de Kleine, R.A.Hendriks, G.J.Kusters, W.J.Broekman, T.G.van Minnen, A.A randomized placebo-controlled trial of d-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiatry 2012; 71(11): 962–968CrossRefGoogle ScholarPubMed
Smits, J.A.Rosenfield, D.Otto, M.W.Powers, M.B.Hofmann, S.G.Telch, M.J.et al.d-Cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry 2013; 73(11):1054–1058CrossRefGoogle ScholarPubMed
Mancebo, M.C.Eisen, J.L.Sibrava, N.J.Dyck, I.R.Rasmussen, S.A.Patient utilization of cognitive-behavioral therapy for OCD. Behav Ther 2011; 42(3): 399–412CrossRefGoogle ScholarPubMed
Santana, L.Fontenelle, J.M.Yucel, M.Fontenelle, L.F.Rates and correlates of nonadherence to treatment in obsessive-compulsive disorder. J Psychiatr Pract 2013; 19(1): 42–53CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.